Protalix BioTherapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 23, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	209	134	117	65	33	97
Market Cap Growth	10.68%	13.82%	80.88%	94.95%	-65.61%	123.36%
Enterprise Value	191	113	104	76	23	115
Last Close Price	2.58	1.73	1.62	1.19	0.71	2.82
PE Ratio	45.44	47.21	15.62	-	-	-
PS Ratio	3.96	2.59	1.98	1.46	0.99	1.88
PB Ratio	4.63	3.20	3.87	-6.52	-6.28	-4.38
P/TBV Ratio	4.63	3.20	3.87	-	-	-
P/FCF Ratio	-	18.73	-	-	-	-
P/OCF Ratio	-	15.96	-	-	-	-
EV/Sales Ratio	3.64	2.19	1.75	1.72	0.68	2.24
EV/EBITDA Ratio	23.38	22.35	9.86	-	-	35.08
EV/EBIT Ratio	35.32	29.80	10.98	-	-	51.93
EV/FCF Ratio	-19.16	15.79	-	-	-	-
Debt / Equity Ratio	0.16	0.13	0.78	-3.15	-5.54	-2.38
Debt / EBITDA Ratio	0.85	0.81	2.00	-	-	11.94
Debt / FCF Ratio	-	0.75	-	-	-	-
Net Debt / Equity Ratio	-0.40	-0.68	-0.55	-1.06	0.91	-0.96
Net Debt / EBITDA Ratio	-2.72	-5.61	-1.57	-0.95	0.28	6.44
Net Debt / FCF Ratio	1.81	-3.96	7.41	-0.44	0.47	-0.97
Asset Turnover	0.86	0.68	0.93	0.74	0.54	1.11
Inventory Turnover	1.37	1.21	1.28	1.13	1.05	1.02
Quick Ratio	2.00	1.49	1.11	0.84	1.29	0.48
Current Ratio	3.03	2.35	1.54	1.38	1.86	0.64
Return on Equity (ROE)	12.64%	7.64%	72.50%	-	-	-
Return on Assets (ROA)	5.53%	3.10%	9.32%	-12.57%	-18.06%	2.99%
Return on Invested Capital (ROIC)	19.78%	18.94%	127.32%	-	-	-
Return on Capital Employed (ROCE)	10.60%	8.20%	26.90%	-55.70%	-50.50%	-14.60%
Earnings Yield	2.20%	2.12%	6.40%	-21.50%	-72.80%	-5.50%
FCF Yield	-4.77%	5.34%	-1.90%	-36.92%	-31.00%	-22.59%
Buyback Yield / Dilution	-15.89%	1.66%	-70.04%	-9.81%	-51.43%	-96.44%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.